课题基金 / 基金详情

项目摘要

项目成果

Alex Jordan Harvey的其他基金

相似基金

相关文献

中文摘要
翻译
点击翻译按钮获取中文摘要
英文摘要
DESCRIPTION (provided by applicant): The impact of protein-based pharmaceuticals in the treatment of disease continues to surge, driven by discoveries in genomics and successful implementation by the biotechnology industry. The production of proteins remains a challenge because of the increasing demand and need for large doses. Many proteins require post-translational modifications that are only efficiently synthesized by vertebrate cells. Vertebrate cells, such as the industry standard Chinese Hamster Cells (CHO), can be difficult to grow under GMP conditions and require immense resources to propagate at the scale needed to meet market demands. Animal and plant based bioreactors systems are an attractive alternative to CHO due to low maintenance costs and ease of scalability. However, the post-translational modification of biopharmaceuticals, in particular glycosylation, is executed differently in animals and plants as compared to CHO cells. The hen, because of its prolific egg laying and protein production abilities, has been pursued as a biopharmaceutical bioreactor. The sugar molecules attached to certain proteins produced in eggs of transgenic hens have been found to share the same basic structure with CHO and human proteins. However there are some structural elements that are lacking in the egg white-derived sugars that could be important for bioactivity and bioavailability in human patients. The goal of this project is to genetically engineer hens to make wholly-human like sugar structures in egg white-derived biopharmaceuticals. Project Narrative The proposed project, creation of transgenic hens that produce human biopharmaceuticals with human-like characteristics, will be a major step in the maturation of a production technology that will have dramatic effects on the biopharmaceutical industry. In the near future, consumers will have access to the first generation of chicken-produced drugs and will benefit from the greatly reduced cost as well as increased safety and efficacy of such drugs.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
Targeting aberrant glycopeptide tumor antigens for generation of novel cancer therapeutics with enhanced selectivity and utility
  • 批准号:
    9551654
  • 项目类别:
  • 资助金额:
    $21.29万
  • 财政年份:
    2017
  • 负责人:
    Alex Jordan Harvey
  • 依托单位:
Antibodies to O-GlcNAc modified histones for chromatin biology and epigenetic res
  • 批准号:
    8713185
  • 项目类别:
  • 资助金额:
    $34.92万
  • 财政年份:
    2014
  • 负责人:
    Alex Jordan Harvey
  • 依托单位:
Avian transgenesis via site-directed integration
  • 批准号:
    6930675
  • 项目类别:
  • 资助金额:
    $40.94万
  • 财政年份:
    2004
  • 负责人:
    Alex Jordan Harvey
  • 依托单位:
Avian transgenesis via site-directed integration
  • 批准号:
    7056763
  • 项目类别:
  • 资助金额:
    $33.68万
  • 财政年份:
    2004
  • 负责人:
    Alex Jordan Harvey
  • 依托单位:
海外基金